Literature DB >> 22551476

Synthesis of double mesoporous core-shell silica spheres with tunable core porosity and their drug release and cancer cell apoptosis properties.

Ahmed Mohamed El-Toni1, Aslam Khan, Mohamed Abbas Ibrahim, Joselito Puzon Labis, Gamal badr, Mansour Al-Hoshan, Shu Yin, Tsugio Sato.   

Abstract

In this work, we demonstrate a simple two-pot approach to double mesoporous core-shell silica spheres (DMCSSs) with uniform size of 245-790 nm, shell thickness of 41-80 nm and surface area and total pore volume of 141-618 m(2) g(-1) and 0.14-0.585 cc g(-1), respectively. First, solid silica spherical particles were synthesized by the Stöber method and used as a core. Second, a mesoporous shell could be formed around the silica cores by using an anionic surfactant and a co-structure directing agent. It was found that mesopores can be anchored within dense silica cores during mesoporous silica shell formation, synchronously the base group with surfactant assistant can etch the dense silica cores to re-organize new mesostructure, so that double mesoporous core-shell silica sphere (DMCSS) structure can be obtained by a single surfactant-templating step. The spherical size and porosity of the silica cores of DMCSS together with shell thickness can be tuned by controlling Stöber parameters, including the concentrations of ammonia, solvent and tetraethoxysilane and the reaction time. DMCSS were loaded with ketoprofen and thymoquinone, which are an anti-inflammatory and a potential novel anti-cancer drug, respectively. Both drugs showed controlled release behavior from the pores of DMCSS. Drug uptakes within DMCSS were ~27 and 81 wt.% for ketoprofen and thymoquinone, respectively. Furthermore, DMCSS loaded with thymoquinone was more effective in inducing cancer cell apoptosis than uncontained thymoquinone, because of the slow release of the drug from the mesoporous structure.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551476     DOI: 10.1016/j.jcis.2012.04.006

Source DB:  PubMed          Journal:  J Colloid Interface Sci        ISSN: 0021-9797            Impact factor:   8.128


  6 in total

Review 1.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

2.  Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release.

Authors:  Samar A Shahein; Khaled AbouAitah; Ahmed M Aboul-Enein; Iman M Higazy; Faten Abou-Elella; Witold Lojkowski; Esam R Ahmed; Shaker A Mousa
Journal:  Int J Nanomedicine       Date:  2019-07-19

Review 3.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

4.  Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types.

Authors:  Gamal Badr; Mohamed K Al-Sadoon; Mostafa A Abdel-Maksoud; Danny M Rabah; Ahmed M El-Toni
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

5.  Optimization of synthesis parameters for mesoporous shell formation on magnetic nanocores and their application as nanocarriers for docetaxel cancer drug.

Authors:  Ahmed Mohamed El-Toni; Mohamed Abbas Ibrahim; Joselito Puzon Labis; Aslam Khan; Mansour Alhoshan
Journal:  Int J Mol Sci       Date:  2013-05-30       Impact factor: 5.923

Review 6.  Thymoquinone, as an anticancer molecule: from basic research to clinical investigation.

Authors:  Md Asaduzzaman Khan; Mousumi Tania; Shangyi Fu; Junjiang Fu
Journal:  Oncotarget       Date:  2017-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.